NEXT-GEN Medicine: Designing Drugs to Fit Patient Profiles

References

1. HoD. QuakeS.R. McCabeE.R.B. Enabling technologies for personalized and precision medicine.Trends Biotechnol.202038549751810.1016/j.tibtech.2019.12.021 31980301
   [Google Scholar]
2. RadhakrishnanA. KuppusamyG. PonnusankarS. ShanmukhanN.K. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.Pharmacogenomics J.202020111810.1038/s41397‑019‑0135‑8 31819163
   [Google Scholar]
3. AkhoonN. Precision medicine: A new paradigm in therapeutics.Int. J. Prev. Med.20211211210.4103/ijpvm.IJPVM_375_19 34084309
   [Google Scholar]
4. WeinshilboumRM WangL Precision medicine: A new paradigm in therapeutics.Mayo Clin Proc 201721921117112210.1016/j.mayocp.2017.09.001
   [Google Scholar]
5. HasanzadM. Principles of pharmacogenomics and pharmacogenetics. Precision medicine in clinical practice. Singapore: Springer.Nature Singapore2022133210.1007/978‑981‑19‑5082‑7_2
   [Google Scholar]
6. HasanzadM. SarhangiN. NaghaviA. Genomic medicine on the frontier of precision medicine.J. Diabetes Metab. Disord.202121185386110.1007/s40200‑021‑00880‑6 35673457
   [Google Scholar]
7. HippmanC. NislowC. Pharmacogenomic testing: Clinical evidence and implementation challenges.J. Pers. Med.2019934010.3390/jpm9030040 31394823
   [Google Scholar]
8. KohnoT. KatoM. KohsakaS. C-CAT: The national datacenter for cancer genomic medicine in Japan.Cancer Discov.202212112509251510.1158/2159‑8290.CD‑22‑0417 36321305
   [Google Scholar]
9. Serelli-LeeV. ItoK. KoibuchiA. A state-of-the-art roadmap for biomarker-driven drug development in the era of personalized therapies.J. Pers. Med.202212566910.3390/jpm12050669 35629092
   [Google Scholar]
10. SarduM.L. PoggesiI. De NicolaoG. Biomarker- versus drug-driven tumor growth inhibition models: An equivalence analysis.J. Pharmacokinet. Pharmacodyn.201542661162610.1007/s10928‑015‑9427‑z 26209955
    [Google Scholar]
11. BischoffP. Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for nonsquamous programmed death-ligand 1-high (≥50%) NSCLC in the german national network genomic medicine lung cancer.J. Thorac. Oncol.20241925803817
    [Google Scholar]
12. ÖzenverN. EfferthT. Identification of prognostic and predictive biomarkers and druggable targets among 205 antioxidant genes in 21 different tumor types via data-mining.Pharmaceutics202315242710.3390/pharmaceutics15020427 36839749
    [Google Scholar]
13. SahuT. RatreY.K. ChauhanS. BhaskarL.V.K.S. NairM.P. VermaH.K. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science.J. Drug Deliv. Sci. Technol.20216310248710.1016/j.jddst.2021.102487
    [Google Scholar]
14. De MatteisL. Martín-RapúnR. de la FuenteJ.M. Nanotechnology in personalized medicine: A promising tool for alzheimer’s disease treatment.Curr. Med. Chem.201825354602461510.2174/0929867324666171012112026 29022501
    [Google Scholar]
15. AlghamdiM.A. FallicaA.N. VirzìN. KesharwaniP. PittalàV. GreishK. The promise of nanotechnology in personalized medicine.J. Pers. Med.202212567310.3390/jpm12050673 35629095
    [Google Scholar]
16. KépesZ. AratóV. SzabóJ.P. Therapeutic performance evaluation of 213bi-labelled Aminopeptidase N (APN/CD13)-affine NGR-Motif ([213Bi]Bi-DOTAGA-cKNGRE) in experimental tumour model: A treasured tailor for oncology.Pharmaceutics202315249110.3390/pharmaceutics15020491 36839813
    [Google Scholar]
17. LepowskyE. TasogluS. 3D printing for drug manufacturing: A perspective on the future of pharmaceuticals.Int. J. Bioprint.201841119
    [Google Scholar]
18. LamE.H.Y. YuF. ZhuS. WangZ. 3D bioprinting for next-generation personalized medicine.Int. J. Mol. Sci.2023247635710.3390/ijms24076357 37047328
    [Google Scholar]
19. ParulskiC. ByaL.A. GoebelJ. ServaisA.C. LechanteurA. EvrardB. Development of 3D printed mini-waffle shapes containing hydrocortisone for children’s personalized medicine.Int. J. Pharm.202364212313110.1016/j.ijpharm.2023.123131 37321464
    [Google Scholar]
20. MaguireR. McCannL. KotronoulasG. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).BMJ2021374: n1647.10.1136/bmj.n1647 34289996
    [Google Scholar]
21. GukK. HanG. LimJ. Evolution of wearable devices with real-time disease monitoring for personalized healthcare.Nanomaterials (Basel)20199681310.3390/nano9060813 31146479
    [Google Scholar]
22. TylerJ. ChoiS.W. TewariM. Real-time, personalized medicine through wearable sensors and dynamic predictive modeling: A new paradigm for clinical medicine.Curr. Opin. Syst. Biol.202020172510.1016/j.coisb.2020.07.001 32984661
    [Google Scholar]
23. HuangX. ZhouY. TangH. LiuB. SuB. WangQ. Differential metabolic network construction for personalized medicine: Study of type 2 diabetes mellitus patients’ response to gliclazide-modified-release-treated.J. Biomed. Inform.202111810379610.1016/j.jbi.2021.103796 33932596
    [Google Scholar]
24. El-GendyD.M. MohamedM.A. AmirghasemiF. AttyS.A. Abd El-RahmanM.K. MousaviM.P.S. From aluminum foil to personalized medicine: Ecofriendly one-step electrode modification for rapid detection of ertapenem and co-administered medications.J. Sci. Adv. Mater. Devices20238310060110.1016/j.jsamd.2023.100601
    [Google Scholar]
25. WangJ.F. ZhangT.L. FuB.J. A measure of spatial stratified heterogeneity.Ecol. Indic.20166725025610.1016/j.ecolind.2016.02.052
    [Google Scholar]
26. WesselingH. Tau PTM profiles identify patient heterogeneity and stages of alzheimer’s disease.Cell2020183616991713.e1310.1016/j.cell.2020.10.029
    [Google Scholar]
27. TurashviliG. BrogiE. Tumor heterogeneity in breast cancer.Front. Med. (Lausanne)2017422710.3389/fmed.2017.00227 29276709
    [Google Scholar]
28. KentD.M. SteyerbergE. van KlaverenD. Personalized evidence based medicine: Predictive approaches to heterogeneous treatment effects.BMJ2018363k424510.1136/bmj.k4245 30530757
    [Google Scholar]
29. NeelandI.J. PoirierP. DesprésJ.P. Cardiovascular and metabolic heterogeneity of obesity: Clinical challenges and implications for management.Circulation2018137131391140610.1161/CIRCULATIONAHA.117.029617 29581366
    [Google Scholar]
30. SchernthanerG. Schernthaner-ReiterM.H. Diabetes in the older patient: Heterogeneity requires individualisation of therapeutic strategies.Diabetologia20186171503151610.1007/s00125‑018‑4547‑9 29417185
    [Google Scholar]
31. Rubio-PerezC. GuneyE. AguilarD. Genetic and functional characterization of disease associations explains comorbidity.Sci. Rep.201771620710.1038/s41598‑017‑04939‑4 28740175
    [Google Scholar]
32. RyanJ. FransquetP. WrigglesworthJ. LacazeP. Phenotypic heterogeneity in dementia: A challenge for epidemiology and biomarker studies.Front. Public Health2018618110.3389/fpubh.2018.00181 29971228
    [Google Scholar]
33. DeliuM. YavuzT.S. SperrinM. Features of asthma which provide meaningful insights for understanding the disease heterogeneity.Clin. Exp. Allergy2018481394710.1111/cea.13014 28833810
    [Google Scholar]
34. van HamburgJ.P. TasS.W. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis.J. Autoimmun.201887698110.1016/j.jaut.2017.12.006 29254845
    [Google Scholar]
35. GhasemiM. NabipourI. OmraniA. AlipourZ. AssadiM. Precision medicine and molecular imaging: New targeted approaches toward cancer therapeutic and diagnosis.Am. J. Nucl. Med. Mol. Imaging201666310327 28078184
    [Google Scholar]
36. KrzyszczykP. The growing role of precision and personalized medicine for cancer treatment.Technology201806 03n047910010.1142/S2339547818300020
    [Google Scholar]
37. GambardellaV. TarazonaN. CejalvoJ.M. Personalized medicine: Recent progress in cancer therapy.Cancers (Basel)2020124100910.3390/cancers12041009 32325878
    [Google Scholar]
38. GaoM. HarperM.M. LinM. development of a single-cell technique to increase yield and use of gastrointestinal cancer organoids for personalized medicine application.J. Am. Coll. Surg.2021232450451410.1016/j.jamcollsurg.2020.11.009 33253861
    [Google Scholar]
39. WahbiW. KorelinK. SieviläinenM. Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma.Transl. Oncol.20233310167710.1016/j.tranon.2023.101677 37099957
    [Google Scholar]
40. HungS.I. ChuM.T. HouM.M. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.Biomed. Pharmacother.202316911592810.1016/j.biopha.2023.115928 38011788
    [Google Scholar]
41. TadaH. FujinoN. NomuraA. Personalized medicine for cardiovascular diseases.J. Hum. Genet.2021661677410.1038/s10038‑020‑0818‑7 32772049
    [Google Scholar]
42. FurkelJ. KnollM. DinS. C-MORE: A high-content single-cell morphology recognition methodology for liquid biopsies toward personalized cardiovascular medicine.Cell Rep. Med.202121110043610.1016/j.xcrm.2021.100436 34841289
    [Google Scholar]
43. SugandhF.N.U. ChandioM. RaveenaF.N.U. Advances in the management of diabetes mellitus: A focus on personalized medicine.Cureus2023158e4369710.7759/cureus.43697 37724233
    [Google Scholar]
44. JoshiS. ShamannaP. DharmalingamM. Digital twin-enabled personalized nutrition improves metabolic dysfunction-associated fatty liver disease in type 2 diabetes: results of a 1-year randomized controlled study.Endocr. Pract.2023291296097010.1016/j.eprac.2023.08.016 37778441
    [Google Scholar]
45. MengX. WangF. GaoX. Association of IgG N-glycomics with prevalent and incident type 2 diabetes mellitus from the paradigm of predictive, preventive, and personalized medicine standpoint.EPMA J.202214112010.1007/s13167‑022‑00311‑3 36866157
    [Google Scholar]
46. Griñán-FerréC. Bellver-SanchisA. GuerreroA. PallàsM. Advancing personalized medicine in neurodegenerative diseases: The role of epigenetics and pharmacoepigenomics in pharmacotherapy.Pharmacol. Res.202420510724710.1016/j.phrs.2024.107247 38834164
    [Google Scholar]
47. Iturria-MedinaY. CarbonellF.M. EvansA.C. Multimodal imaging-based therapeutic fingerprints for optimizing personalized interventions: Application to neurodegeneration.Neuroimage2018179405010.1016/j.neuroimage.2018.06.028 29894824
    [Google Scholar]
48. CipollaD. WuH. GondaI. EastmanS. RedelmeierT. ChanH.K. Modifying the release properties of liposomes toward personalized medicine.J. Pharm. Sci.201410361851186210.1002/jps.23969 24715635
    [Google Scholar]
49. PardeikeJ. StrohmeierD.M. SchrödlN. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.Int. J. Pharm.201142019310010.1016/j.ijpharm.2011.08.033 21889582
    [Google Scholar]
50. TanY.J.N. YongW.P. KochharJ.S. On-demand fully customizable drug tablets via 3D printing technology for personalized medicine.J. Control. Release2020322425210.1016/j.jconrel.2020.02.046 32145267
    [Google Scholar]
51. WeningK. BreitkreutzJ. Novel delivery device for monolithical solid oral dosage forms for personalized medicine.Int. J. Pharm.20103951-217418110.1016/j.ijpharm.2010.05.036 20635515
    [Google Scholar]
52. PMC.The Scope & Significance of Progress in 2021.Available From: https://www.personalizedmedicinecoalition.org/User-files/PMC-Corporate/file/Personalized_Medicine_at_FDA_ The_Scope_Significance_of_Progress_in_2021.pdf
    [Google Scholar]
53. FDA.Precision Medicine.2021Available From: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine
    [Google Scholar]